Avience has Rs 8-9 crore in reagent-rental analyzers
Key highlights
- Avience said Rs 8-9 crore of analyzers are installed under reagent-rental arrangements.
- Reagent rental accounts for 50% of Avience's trading business, while pure trading accounts for the other 50%.
- The Rs 8-9 crore rental analyzer base compares with almost Rs 19 crore of fixed assets.
- Management said the new facility is expected to require about Rs 35-40 crore of capital expenditure.
powered by IRIS

On the earnings call, Avience said approximately Rs 8-9 crore of analyzers were installed at customer locations on a reagent-rental basis, compared with almost Rs 19 crore of fixed assets. Management said reagent rental represented 50% of Avience's trading business, with the other 50% comprising pure trading.
Know Avience Biomedicals inside out
Results, valuation, peers and who's buying, in one view.
How much has Avience invested in reagent-rental analyzers?
Avience said approximately Rs 8-9 crore of its almost Rs 19 crore fixed-asset base relates to analyzers installed at different locations under reagent-rental arrangements. The disclosed analyzer pool is therefore a substantial component of the fixed assets cited on the call, rather than an immaterial part of the trading operation.
Management did not disclose the number of installed analyzers, customer locations, contract terms, utilization, depreciation or revenue generated by the Rs 8-9 crore asset base. It did explain the mechanism: in the reagent-rental model, Avience invests in the instrument and earns from supplying reagents, rather than selling an analyzer to every customer upfront.
The installed equipment is part of an analyzer business that management said currently serves tier-2 and tier-3 cities and smaller customers, rather than mainly large hospitals and laboratories. Avience said its present self-manufactured analyzers are semi-automatic, whereas large laboratories with high sample volumes require fully automated analyzers.
What share of Avience's trading business is reagent rental?
Avience said reagent rental accounts for 50% of its trading business and pure trading accounts for the other 50%. Management confirmed this is a split within trading, while manufacturing is separately classified as manufacturing rather than as either rental or pure trading.
The 50% figure does not establish reagent rental's share of Avience's total revenue because management did not disclose trading revenue as a proportion of company revenue. It does show that the trading operation combines two equal parts by management's description: customer arrangements where Avience funds an analyzer and arrangements classified as pure trading.
Management described manufacturing as Avience's core business and cited an average manufacturing margin of about 40-50%, depending on the product. For trading, it cited margins of 10-15%, while saying that reagent-rental cases can produce margins of 40-50% in some instances because Avience has invested in the instrument.
Avience did not provide reported revenue, profit, average margin or return on assets for the reagent-rental portfolio. The comparison is therefore between management's stated margin ranges for manufacturing, trading and some rental cases, not a disclosure of audited segment profitability.
Got a follow-up? Ask IRIS
How does Avience link analyzer placements with reagent sales?
Avience said its trading activity includes both analyzers and reagents: some customers buy instruments, while others take an instrument on a reagent-rental basis. Management said this is a mix-and-match model, and it did not say that all large customers use rental arrangements or that all customers purchase analyzers outright.
Avience said it manufactures all reagents at its facility. For analyzers placed in the market from other manufacturers, management said Avience can manufacture and sell reagents for the equipment, although compatibility is not universal because some analyzers operate as closed systems.
Management described a closed system as one controlled through software and barcode settings linking the analyzer and its reagent. Under that arrangement, other reagents cannot be used unless Avience opens the analyzer; if five-channel or 10-channel parameters are opened, compatible five-parameter or 10-parameter reagents from others can also be used.
Avience cited a Mindray analyzer with five open channels as an example where it runs five parameters using reagents manufactured by Avience. Management said that when Avience begins its own analyzer production, its reagents can be used 100% on its own analyzer, while third-party analyzer use remains subject to each system's open or closed configuration.
What could expand Avience's analyzer and reagent model?
Avience said it is validating fully automated analyzers and expects them to start 2-3 months after it receives a licence for the new manufacturing facility. That plan would extend the current semi-automatic analyzer offering toward customers such as larger hospitals and laboratories that require higher sample-processing capacity.
Management said Avience has tie-ups with 2-3 manufacturers for high-performance liquid chromatography, biochemistry and hematology analyzers. Products had arrived from China and were under validation at Avience's facility, where the company said it was adding its own inputs under a Make in India approach that management said requires 25% or more local input.
The proposed capital expenditure for the new facility was initially Rs 30 crore and is now expected to be about Rs 35-40 crore. Management allocated approximately Rs 2 crore to land, Rs 15 crore to the building and about Rs 15 crore to plant and machinery, although those component figures do not explain the full upper end of the revised Rs 35-40 crore estimate.
Avience said it had 117 Central Drugs Standard Control Organization, or CDSCO, licences and 200 products in its pipeline. Management said it hoped to secure 200 additional CDSCO licences within one year and described a longer-term ambition to develop laboratory instruments ranging from semi-automatic machines to equipment capable of processing 1,000 samples an hour.
Conclusion
Avience's disclosure identifies a Rs 8-9 crore installed analyzer base behind its reagent-rental activity, which management said forms half of trading alongside pure trading. The model differs from an outright instrument sale because Avience funds the equipment and seeks reagent business, with access to those reagent sales affected by whether an analyzer is configured as a closed or open system.
The next stated milestones are completion and licensing of the new manufacturing facility, which management said could be ready in the first or second week of December and inaugurated in January 2027, and the start of fully automated analyzers 2-3 months after licensing. Management's targets of 200 additional CDSCO licences within one year and Rs 35-40 crore of facility expenditure are also disclosed matters to watch next.


